How ulcerative colitis medicines affect blood vessel stiffness
Part of Digestive system clinical trials.
This study looks at how common ulcerative colitis treatments (anti-TNF medicines, vedolizumab, or tofacitinib) change the health of your blood vessels. It may help doctors better understand cardiovascular risk in people with ulcerative colitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ulcerative colitis for at least 6 months
- You are 18 years or older
- You are starting a specific ulcerative colitis medicine: infliximab, adalimumab, golimumab, vedolizumab, or tofacitinib
- You can sign a consent form and agree to join
- Your blood pressure, aspirin/antiplatelet, and cholesterol medicines (if you take them) must be at a stable dose for the past 3 months and during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
This study tests whether measuring drug levels in the blood can help doctors find the best dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for people with ulcerative colitis or Crohn's disease. It aims to improve control of these conditions while keeping treatment safe.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study looks at how your blood tests (inflammation levels) change after you start or adjust your treatment for ulcerative colitis or Crohn's disease. It also checks how your gut heals by looking at tissue samples from a follow-up colonoscopy.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.